RxDoctor Payments Data

Alice Fazekas, PA

Medical · Smyrna, GANPI 1295824324

Payments from drug & device makers

$7,473in general payments, 2019–2025

Across 194 payments — averaging $38.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$1K
  • Nevro Corp.$891
  • Abbott$385
  • Saluda Medical Americas, Inc.$345
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$297
  • plus $2K from 30 others

What the payments were for

  • Travel & lodging$72610%
  • Food & beverage$6,69390%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,473 in reported general payments places this provider in the 85th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$10,247
Medicare patients
65
Services billed
124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl28$23,086
MovantikNaloxegol Oxalate26$10,147
Buprenorphine28$7,241
ZtlidoLidocaine15$5,987
Gabapentin286$3,339
Lidocaine18$2,423
Tramadol Hcl131$1,438
Pregabalin71$1,239
Tizanidine Hcl86$673
Methocarbamol60$571
Acetaminophen-CodeineAcetaminophen With Codeine29$446
Cyclobenzaprine Hcl100$384
Diclofenac Sodium30$380
Duloxetine Hcl25$269
Amitriptyline Hcl39$268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$52$23,08628 claims
Redhill Biopharma Inc.Movantik$15$10,14726 claims
Scilex Pharmaceuticals Inc.Ztlido$56$5,98715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 950 medical providers in Georgia.

Other medical in Smyrna

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →